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Summary Hepatic involvement by a T-cell neoplasm is rare and often challenging to diagnose in liver
biopsies. We collected 40 cases of T-cell neoplasms diagnosed in the liver from five large academic
institutions to assess the clinicopathologic features. The patients included 11 women and 29 men, with
a median age of 54 (range: 2e75) years and a high mortality rate (31/37, 83.8%). Fourteen (35%) patients were diagnosed with hepatosplenic T-cell lymphoma (HSTCL), 13 (32.5%) peripheral T-cell
lymphoma, not otherwise specified (PTCL-NOS), and 13 (32.5%) other types of T-cell neoplasms. Patients with HSTCL were much younger and had worse survival than PTCL-NOS and other T-cell neoplasms (P < 0.05). On imaging studies, 20 cases (50%) showed abnormalities, including 10 with mass
lesions that correlated with normal or cholestatic pattern enzyme elevation. Histomorphological analysis revealed four main patterns; with the exception of mass forming lesions (pattern 4; n Z 8), cases
with sinusoidal predominant (pattern 1; n Z 12), portal predominant with sinusoidal infiltrates (pattern
2; n Z 13) or lobular aggregates (pattern 3; n Z 5) demonstrated small to medium lymphocytes resembling a reactive/inflammatory process. In addition, we described two cases of T-cell large granular lymphocytic leukemia that mimicked HSTCL, and a case of aggressive post-transplant lymphoproliferative
disorder that developed after chronic Epstein-barr virus (EBV) infection, suggesting the importance of
EBV testing in some lymphoma cases. As the largest cohort of T-cell neoplasms in liver, our study
provides critical data on disease frequency, distribution, and clinicopathologic features that are
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essential for accurate diagnosis.
© 2020 Elsevier Inc. All rights reserved.

1. Introduction
The liver is not commonly involved with non-Hodgkin
lymphoma, occurring next in frequency to lymph node,
spleen, and bone marrow. Most hepatic lymphomas are
secondary involvement by a systemic disease, frequently
diffuse large B-cell lymphoma, comprising nearly half of
the cases reported [1,2]. Approximately 12% of lymphomas
in the liver are attributed to a T-cell lineage, mostly peripheral T-cell lymphoma, not otherwise specified (PTCLNOS, 9%), followed by anaplastic large cell lymphoma
(ALCL, 2%) and hepatosplenic T-cell lymphoma (HSTCL,
1%) [1]. Owing to their rarity, T-cell lymphomas in the
liver were often reported in single case reports or small case
series [3,4], lacking epidemiologic and systemic clinicopathologic analysis.
The initial lymphoma diagnosis, particularly for T-cell
neoplasms, can be very challenging in small liver biopsies
[3]. For example, both HSTCL and T-cell large granular
lymphocytic leukemia (T-LGL) typically infiltrate the hepatic sinusoids without discrete mass formation, mimicking
a reactive condition. Other lymphomas can have portal and
lobular infiltrates, indistinguishable from viral hepatitis or
drug-induced liver injury by histology alone. Accurate
diagnosis relies on clinical history, immunohistochemistry
(IHC) to determine T-cell lineage and antigen aberrancy,
polymerase chain reaction analysis on T-cell receptors
(TCRs) to establish clonality, and sometimes cytogenetic or
molecular studies to detect disease-specific alterations in
certain lymphomas [5,6]. This poses significant challenges
when limited biopsy material is available for evaluation,
emphasizing the importance of pattern recognition and
selective ancillary tests.
Herein, we performed a multi-institutional retrospective
review of various types of T-cell neoplasms diagnosed in
liver specimens to analyze the essential clinical and histopathologic features.

2. Materials and methods
2.1. Patients and data collection
A text-based search in the electronic pathology database
between 2000 and 2020 was performed collaboratively
across five large academic institutions in the United States.
Clinical information regarding patients’ age, sex, imaging
findings, relevant medical history, clinical presentation
before liver biopsy, treatment, follow-up, and disease

outcomes was collected. When multiple liver specimens
were available for the same patient, the imaging study and
liver function test most pertinent to the final diagnosis were
recorded. In particular, the image findings were divided
into 4 categories: (1) sizable mass lesion (mass); (2) focal
nonspecific abnormality without mass formation
(abnormal); (3) hepatomegaly (enlargement); (4) no abnormality (normal). The liver function tests, including
alanine aminotransferase (ALT), aspartate aminotransferase, alkaline phosphatase (ALP), and total bilirubin
levels were recorded for the highest value within one month
before the biopsy or autopsy. A ratio (R) value, defined as
ALT/upper limit of normal: ALP/upper limit of normal,
was applied to designate the pattern of liver injury, namely,
hepatitis pattern if R > 5, cholestatic pattern if R < 2, and
mixed pattern if R is between 2 and 5 [7]. This study was
approved by the institutional review boards of all participating medical centers.

2.2. Lymphoma diagnosis, classiﬁcation, and
histomorphologic analysis
The pathology report and diagnosis for each case were
reviewed by expert hematopathologists at each contributing
institution. The classification of T-cell neoplasms was
based on the 2017 WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues [8]. Specific types of Tcell neoplasms diagnosed in this study included HSTCL,
peripheral T-cell lymphoma, not otherwise specified
(PTCL-NOS), T-LGL, ALK-negative ALCL, cutaneous Tcell lymphoma (CTCL) specifically mycosis fungoides,
angioimmunoblastic T-cell lymphoma (AITL), posttransplant lymphoproliferative disorder (PTLD), extranodal NK/T-cell lymphoma, nasal type (NK/T), T-prolymphocytic leukemia (T-PLL), and T-cell acute
lymphoblastic leukemia (T-ALL). When applicable, a
“primary” hepatic lymphoma is defined as lymphoma either
confined to the liver or having initial and major liver
involvement before spreading to other anatomic sites. A
“secondary” hepatic lymphoma is defined when there is
prior or concurrent systemic disease, or the same lymphoma has been diagnosed at other anatomic sites before
liver involvement [9e11].
The histomorphology and infiltration pattern of lymphoma cells in relationship to liver parenchyma (portal,
sinusoidal, and lobular), as well as the size of lymphoma
cells in comparison to the nuclei of macrophages or
endothelial cells (small, medium, and large) were recorded
for each case based on slide review.
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Clinical and pathological characteristics of T-cell neoplasms in liver.

Patient Diagnosis Age Sex Pertinent clinical
history

F/U Outcome Imaging
(days)

R
Histology pattern
value

Main immunophenotype

Clonality Molecular/cytogenetics

DOD

Abnormal NL

Sinusoidal þ portal

CD3þ, CD4-, CD8-, CD5-, CD56-, TCRgd
TIA-1þ, TDT-

DOD

Normal

0.1

Portal þ sinusoidal

DOD

Normal

0.2

Sinusoidal

31 M Recurrent HSTCL, 215
s/p CTx and SCT
49 M Presented with
6
HLH

DOD

Normal

1.2

Sinusoidal

DOD

Normal

1.1

Portal þ sinusoidal

CD3þ, CD4þ, CD7-, CD30-, CD56-, TCRab
CD57þ/, TIA1þ
CD2þ, CD3þ, CD4-, CD8-, CD5-, TCRgd
CD7þ, CD30-, TIA1þ, granzyme BCD2þ, CD3-, CD4-, CD8-, CD7þ/ TCRgd
, TIA1þ, granzyme B-, EBVCD2-, CD3þ, CD4-, CD8-, CD5-,
CD7-

6

47 M None

32

DOD

Enlarged 32.2 Sinusoidal

7
8

71 M None
4 M None

14
0

DOD
DOD

9

30 M Ulcerative colitis

89

DOD

10

21 M None

N/A

LTF

11

60 F

37

DOD

12

30 M Ulcerative colitis,
PSC, AIH

NA

DOD

13

33 M None

619

DOD

14

31 M Presented with
HLH
61 M None

13

DOD

76

DOD

None

14

DOD

1

2
3
4
5

15
16
17
18

HSTCL 3 F
(n Z 14,
35%)
55 M

Mixed phenotype 107
acute leukemia, s/p
CTx
Cutaneous DLBCL, 99
s/p CRTx and SCT
60 M None
65

PTCLNOS
(n Z 13, 70 F
32.5%)
55 F

None

PTCL in LN x
N/A LTF
4 yrs, s/p CTx
27 M EVAN’S syndrome 2600 Alive

CD2þ, CD3þ, CD4-, CD8-, CD5þ,
CD7-, CD30-, CD56þ/, EBVNormal 0.4 Portal þ Sinosoidal
CD3þ, CD25þ, CD30-, EBVNormal N/A Portal
CD2þ, CD3þ, CD4-, CD8-, CD5-,
aggregates þ sinusoidal CD7þ, CD25-, CD30-, CD56þ,
TIA1þ
Normal 14.2 Sinosoidal
CD3þ, CD4-, CD8þ, CD5-, CD16þ,
CD56þ, CD57þ
Enlarged NL Sinusoidal
CD2þ, CD3þ, CD4-, CD8þ, CD5-,
CD7þ, CD25-, CD57Enlarged 0.3 Sinusoidal þ portal
CD3þ, CD4-, CD8-, CD5þ/,
CD30-, CD56-, CD57þ/, TIA1þ,
EBVAbnormal 0.7 Sinusoidal
CD2þ/, CD3þ, CD4-, CD8-, CD5, CD7þ, CD30-, CD56þ, TIA1þ,
EBV-, ALKNormal 1.2 Portal
CD2þ, CD3þ, CD4-, CD8þ, CD5þ/
, CD7þ/, CD56-, CD57-, TIA1þ,
granzyme Bþ, EBVNormal 1.4 Sinusoidal þ portal
CD2-, CD3þ, CD4-, CD8-, CD5-,
CD7þ/, TIA1þ, EBVMass
NL Mass
CD2þ, CD3þ, CD4-, CD8-, CD5-,
CD7þ/, CD30þ/, CD56-, TIA1Normal 5.5 Portal þ lobular
CD2þ, CD3þ, CD4þ, CD8þ, CD5-,
aggregates
CD7-, TIA1þ, granzyme BMass
N/A portal large
CD3þ, CD4þ, CD8-, CD5þ, CD7þ/
aggregates þ lobules , CD30-, EBV-, ALKMass
1.7 Mass
CD3þ, CD4þ, CD8-, CD5þ, CD7þ/

Isochromosome 7q

Monosomy 7
46,XY,del(13)(q14q22),
47,idem,þX and
92,XXYY
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Table 1

TCRgd

TCRgd
TCRab
TCRgd

TCRgd

TCRgd

TCRab

TCRab
(continued on next page)

3

4

Patient Diagnosis Age Sex Pertinent clinical
history

F/U Outcome Imaging
(days)

R
Histology pattern
value

19

69 M PTCL in LN x
2 mos

213

20

59 F

PTCL in LN x
25
8 yrs, s/p SCT
57 M Involving liver first 30
then LN
54 M PTCL in LN x 1 yr 72

21
22

23

70 M PTCL in LN x 1yr, 206
plasma cell
dyscrasia
51 M PTCL in LN x
35
6 mos

24

25

54 M Synchronous LN
and liver
involvment
25 M PTCL in LN x
3 mos

26

27
28

31
32
33

Normal

NL

DOD

Normal

1.5

, CD30-, CD56-, graznyme Bþ
Portal large
CD2þ, CD3þ, CD4-, CD8þ, CD7þ, TCRab
aggregates þ sinosoidal CD30-, CD56þ/, TIA1þ,
granzyme Bþ, EBV-, ALKPortal þ sinusoidal
CD3þ, CD8-, CD5þ, CD7-,

DOD

Normal

0.9

Portal massive

CD2þ, CD3þ, CD4þ, CD5þ, EBV-

DOD

Normal

0.4

Portal þ sinusoidal

DOD

Abnormal N/A Portal

CD2þ, CD3þ, CD4þ, CD8-, CD5þ,
CD7þ/, CD25þ, CD30þ/,
CD56þ/, TIA1þ, granzyme B-,
EBVTCRab
CD2þ, CD3þ, CD4þ, CD5þ,
CD7þ, EBV-

Alive

Enlarged 0.2

Portal

LTF

Normal

Portal þ lobular
þ sinusoidal

9.7

1800 DOD

Enlarged 0.4

Sinusoidal

73 M PTCL in BM x 1 yr 1629 Alive

Enlarged NL

Portal þ sinusoidal

74 M None

Alive

Normal

NL

Sinusoidal

S/p liver transplant 108
for biliary atresia

Alive

Normal

3.5

Sinusoidal þ portal

ALCL
(n Z 2,
5%)

71 M Involving liver first, 52
then CSF
62 M ALCL x 13 yrs
360

DOD

Mass

0.7

Mass

DOD

Mass

1.9

Mass

CTCL
(n Z 2,
5%)

73 F

850

DOD

Normal

0.2

Unknown

152

DOD

Mass

0.4

Portal þ sinusoidal

2

F

Skin x 3 yrs

53 M Skin, s/p CRTx;
Hepatitis C

Clonality Molecular/cytogenetics

DOD

132

T-LGL
(n Z 2,
5%)

29

30

N/A

Main immunophenotype

STAT5 mutation

Trisome 7

TCRab
CD3þ, CD4þ, CD8þ/, CD5þ,
CD7þ/, CD30þ/, CD57þ/,
PD1þ, BCL6-, CD10-, CXCL13-,
EBVCD3þ, CD4þ, CD8-, CD5þ, CD30-, TCRab
CD56-, TIA1þ, EBV-

Normal cytogenetics

TCRab

Normal cytogenetics

TCRab

Normal cytogenetics

CD2þ, CD3þ, CD8þ, CD5þ,
CD7þ, CD30-, CD56þ/, CD57þ,
TIA1þ, granzyme Bþ, EBVCD2þ, CD3þ, CD4þ, CD8-, CD5þ/
, CD7þ/, CD30CD2þ, CD3þ, CD4-, CD8þ, CD5-,
CD7-, CD30-, CD56-, CD57þ,
TIA1þ, granzyme Bþ, EBV-, ALKCD2þ CD3þ CD4-CD8þ CD5þ
CD7  CD56- CD57þ TIA1þ
Granzume B þ EBVCD3þ, CD30þ, ALKCD2þ, CD4þ/, CD30þ, EBV-,
ALKCD2þ, CD3þ, CD4-, CD8-, CD5þ,
CD7-, CD30-, ALKCD2þ, CD3þ, CD4þ, CD8-, CD5þ,
CD7-, CD30-, CD56-, CD57-, EBV-

Normal cytogenetics

TCRab

TCRab
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Table 1 (continued )

75 F

AITL in LN x
12 yrs, s/p CTx
43 M AITL in LN x
2 yrs; Hepatitis C
46 F S/p Liver transplant
for congenital
hepatic fibrosis
9 F Presented with
HLH, s/p SCT

658

Alive

Mass

NL

Mass

747

DOD

Normal

5.3

Unknown

4

DOD

Normal

0.8

Portal aggregates
þ sinusoidal

321

DOD

Mass

NL

mass

16.7 Portal
þ lobular
NL Portal
þ sinusoidal

35

AITL
(n Z 2,
5%)

36

PTLD

37

PTLD

38

NK/T

62 M Skin x 1 yr

1142 DOD

Normal

39

T-PLL

55 F

2505 DOD

Mass

40

T-ALL

70

Mass

T-PLL in BM x
1 yr, s/p CTx and
SCT
38 M T-ALL in BM x
3 mos

DOD

NL

Mass

CD2þ, CD3þ, CD8þ, CD30þ,
PD1þ, Bcl6þ, CD10þ/, EBVCD2þ, CD3þ, CD4þ, CD8-, CD5þ, TCRab
CD7-, CD30-, EBVþ
TCRab
CD3þ, CD4þ, CD8-, CD30þ,
CD56-, CD57-, TIA1þ, granzyme
Bþ, EBVþ, ALKCD2þ, CD3þ, CD4þ, CD8-, CD5-, TCRab
CD7-, CD30þ, CD56þ, CD57-,
TIA1þ, granzyme Bþ, EBVþ, ALKCD3þ, CD4-, CD8-, CD7þ, CD56þ,
TIA1þ, granzyme Bþ, EBVþ
CD3þ, CD4þ, CD8-, CD5þ, CD7þ

Complex
abnormalitya
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CD2þ, CD3þ, CD5-, CD7-

HSTCL, hepatosplenic T-cell lymphoma; PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified; T-LGL, T-cell large granular lymphocytic leukemia; ALCL, anaplastic large cell lymphoma;
CTCL, cutaneous T-cell lymphoma; AITL, angioimmunoblastic T-cell lymphoma; PTLD, post-transplant lymphoproliferative disorder; NK/T, NK/T-cell lymphoma; T-PLL, T-prolymphocytic leukemia; TALL, T-cell acute lymphoblastic leukemia; B, biopsy; A, autopsy; BM, bone marrow; LN, lymph node; CSF, cerebrospinal fluid; s/p, status post; CTx, chemotherapy; CRTx, chemoradiation; SCT, stem cell
transplant; DLBCL, diffuse large B-cell lymphoma; HLH, hemophagocytic lymphohistiocytosis; PSC, primary sclerosing cholangitis; AIH, autoimmune hepatitis; yr, year; mo, month; ICE, ifosfamide,
carboplatin and etoposide; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin hydrochloride; CVAD, cyclophosphamide, vincristine, doxorubicin, and dexamethasone; ESHAP,
etoposide, methylprednisolone, cytarabine, cisplatin; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone, DHAP, dexamethasone, cytarabine, cisplatin; BEAM, carmustine, etoposide,
cytarabine, melphalan; CHOEP, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone; FMR, fludarabine, mitoxantrone and rituximab; FC, fludarabine, cyclophosphamide; S-HAM,
sequential high-dose cytarabine and mitoxantrone; N/A, not applicable; F/U, follow-up; DOD, dead of disease; LTF, lost to follow-up; R, ratio; NL, normal; EBV, Epstein-barr virus; TCRs, T-cell receptors.
* CBC, complete blood count; WBC, white blood cell (x1000/uL); Hb, hemoglobin (g/dL); Hct, hematocrit (%); Plt, platelets (x1000/uL).
a
52e53,XY,add(2)(q35),del(6)(p21),?add(6)(?p23),þadd(7)(q36)x2,þ8,þ20,þ20,þ21,þ21,þi(21)(q10),þmar[cp14]/46,XY[6].
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Fig. 1 Kaplan-Meier survival analysis in patients with T-cell neoplasms in liver. (A) Patients of HSTCL had worse clinical course than
PTCL-NOS, but the difference did not reach statistical significance (P Z 0.078). The clinical course was significantly worse in patients
with HSTCL when compared with other types of T-cell lymphomas except HSTCL and PTCL-NOS (A), or when compared with all nonHSTCL T-cell neoplasms (B). HSTCL, hepatosplenic T-cell lymphoma; PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified.

2.3. Statistical analysis
Clinicopathologic characteristics were coded as numerical (e.g. age), categorical (e.g. R value, lymphoma infiltration pattern, and lymphoma classification), or
dichotomous (e.g. sex). Student’s t-test, chi-square or
Fisher’s exact test, and Kaplan-Meier survival analysis
were performed for statistical significance using Prism
8.3.0 (GraphPad Software, San Diego, CA, USA). P-values
less than 0.05 were considered statistically significant.

3. Results
3.1. Demographic and clinical data
A total of 40 patients, 11 women and 29 men, were
included in this study (Table 1 and Supplementary Table 1).
The median age was 54 (range: 2e75) years; 4 (10%) were
pediatric patients (<18 years old). Fever (n Z 13), jaundice
(n Z 8), and weight loss (n Z 8) were the most common
presenting clinical symptoms. More than half of the cases
(n Z 24) showed pancytopenia in peripheral blood. Liver
function test ranged from normal to the highest of 2200 IU/
L for ALT, 1300 IU/L for ALP, and 28.7 mg/dL for total
bilirubin. The majority of cases (n Z 20) presented with
cholestatic pattern liver enzyme abnormality, followed by
hepatitis pattern (n Z 6) and mixed (n Z 1). Nine patients
had normal liver function test at the time of biopsy. On
imaging studies, half of the patients (n Z 20) had no overt
abnormalities, 10 had discrete mass lesions, 6 diffuse hepatomegaly/enlargement, and 4 focal abnormality other
than mass. A total of 19 (47.5%) cases were liver primary,
whereas 21 (52.5%) were secondary involvement by a
previously diagnosed lymphoma/leukemia. The most
common diagnoses were HSTCL (n Z 14, 35%) and
PTCL-NOS (n Z 13, 32.5%), totaling more than two-thirds
of this study cohort. The remaining 13 patients were
diagnosed as follows: T-LGL (n Z 2, 5%), ALCL (n Z 2,
5%), CTCL (n Z 2, 5%), AITL (n Z 2, 5%), PTLD

(n Z 2, 5%), NK/T (n Z 1, 2.5%), T-PLL (n Z 1, 2.5%),
and T-ALL (n Z 1, 2.5%). Chemotherapy was the main
treatment choices for all T-cell neoplasms. Six patients,
including 3 with HSTCL, 3 with PTCL-NOS and 1 with TPLL underwent stem cell transplant.
Upon follow-up, 31 of 37 (83.8%) patients died of
lymphoma after a median of 82 (range: 0e2505) days,
whereas 6 (16.2%) were alive after a median of 395 (range:
35e2600) days. Three patients were lost to follow-up. Both
HSTCL and PTCL-NOS were highly lethal with a short
overall survival, with even worse prognosis for HSTCL by
Kaplan-Meier survival analysis when compared to nonHSTCL cases (Fig. 1). There were no significant clinical
and survival differences between patients with “primary”
vs. “secondary” T-cell neoplasms in liver (data not shown).

3.2. Histologic analysis and correlation with
imaging and laboratory results
Histomorphologic analysis and correlation with imaging
studies and liver enzymes were performed on all but two
cases. Four major infiltration patterns were summarized
(Fig. 2): sinusoidal predominant (pattern 1; n Z 12), portal
predominant with sinusoidal infiltrates (pattern 2; n Z 13),
portal and lobular infiltrates with lymphoid aggregates
(pattern 3; n Z 5), and mass forming (pattern 4; n Z 8). In
both patterns 1 and 2, the hepatic architecture was relatively preserved with no discrete lymphoid nodules or large
aggregates. Pattern 3 was characterized by lymphoid aggregates or small nodules predominantly in both portal
tracts and lobules (Fig. 3). In pattern 4, the lymphoma
formed mass lesions and effaced the underlying hepatic
architecture by high-grade tumor cells with frequent mitoses and apoptosis (Fig. 4). Pattern 4 almost always
correlated with a sizable “mass” lesion on imaging studies
(Table 1 and Supplementary Table 1). In all patterns,
monotonous lymphoid infiltrates and/or larger cell size
were usually the features that prompted lymphoma workup, especially in cases without a prior lymphoma diagnosis.
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Fig. 2 Histomorphologic analysis of T-cell neoplasms in liver, and correlation with imaging studies and R value of liver enzyme tests.
Number in “()” indicates total number of cases. NL, normal, N/A, not applicable or available.

Fig. 3 T-cell neoplasms exhibiting histology patterns 1 (AeC), 2 (DeF), and 3 (GeI). Pattern 1 was represented by HSTCL with smallsized (A) and medium-sized (B) lymphoid cells expanding the hepatic sinusoid, and T-LGL with classic sinusoidal linear distribution (C).
Pattern 2 was represented by HSTCL (D and E) and PTCL-NOS (F) showing portal and sinusoidal infiltrates. Pattern 3 was represented by
PTCL-NOS (G and H) and NK/T (I) demonstrating prominent lymphoid aggregates in portal tracts and heavy lobular infiltrates.
Magnification: 200. HSTCL, hepatosplenic T-cell lymphoma; PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified.

The lymphoma infiltration pattern did not always
correlate with the pattern of liver function tests; however,
the liver enzyme elevation (R > 5) occurred only in patterns 1 and 3, where lymphoma cells showed predominant

sinusoidal infiltration (2 HSTCL), or lobular aggregates
with hepatocyte injury (2 PTCL-NOS and 1 NK/T). Patterns 2 and 4 more often correlated with a cholestatic
enzyme elevation or normal liver function tests (Fig. 1).
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Fig. 4 T-cell neoplasms exhibiting histology pattern 4 with massive infiltration effacing underlying hepatic structures, represented by
ALCL (A and B), AITL (C), PTCL-NOS (D), T-cell PTLD (E), and T-ALL (F). Magnification: 200. PTCL-NOS, peripheral T-cell
lymphoma, not otherwise specified; ALCL, anaplastic large cell lymphoma; AITL, angioimmunoblastic T-cell lymphoma; PTLD, posttransplant lymphoproliferative disorder.

3.3. Comparisons between HSTCL and PTCL-NOS
Since HSTCL and PTCL-NOS were the most frequent
diagnoses in our cohort, each comprising approximately
one third of the total cases, we compared these two lymphoma types regarding clinicopathologic features (Table 2).
Patients with HSTCL were much younger than those of
PTCL-NOS (median age 31 vs. 55, P Z 0.018). Both were
male predominant. For HSTCL, 2 patients had prior history
of hematopoietic malignancies other than HSTCL, 2 had
history of ulcerative colitis, and 2 presented with hemophagocytic lymphohistiocytosis (HLH) before lymphoma
diagnosis. Most patients with HSTCL had either spleen
and/or bone marrow involvement with typical sinusoidal
infiltration. Involvement of the appendix and lymph node in
one case (patient 8) was also noted. On imaging studies,
three cases showed hepatomegaly and two revealed focal
abnormality, whereas all others had normal imaging findings. Liver function tests were predominantly cholestatic
(n Z 9/14, 64%). Immunophenotypes were mostly CD3þ/
CD4-/CD8-/TIA1þ/TCRgd consistent with non-activated
cytotoxic gamma/delta T-cells. In comparison, patients
with PTCL-NOS usually had no history of other lymphomas or immunosuppression. The majority had established PTCL-NOS diagnoses in lymph nodes (10/13, 77%),
spleen (2/13, 15%), and/or bone marrow (2/13, 15%) before
liver involvement. Only two patients (patients 15 and 18)
had exclusive liver involvement, both showing mass lesions
on imaging studies and a normal or cholestatic liver function test, suggesting “primary” hepatic PTCL-NOS. Histologically, all HSTCL cases presented as small to mediumsized lymphoid cells with sinusoidal infiltrates corresponding to pattern 1 (9/14, 64%) or pattern 2 (5/14, 36%),

whereas PTCL-NOS showed all four histology patterns
though the majority demonstrated portal infiltrates corresponding to patterns 2 or 3 (9/13, 69%) (Figs. 2 and 3). In
contrast to HSTCL, immunophenotypes in PTCL-NOS
were mostly CD3þ/CD4þ/CD8-/TCRab, with rare CD4/
CD8 double negative or double positive cases. Although all
patients with HSTCL died of disease after a median followup of 51 (range: 0e619) days, at least one patient with
primary hepatic PTCL-NOS survived after stem cell
transplant on a follow-up of 2600 days.

3.4. Other lymphomas
Two T-LGL were identified in our cohort (Table 1 and
Supplementary Table 1). One was a 74-year-old men (patient 28) with no significant past medical history, the other
one was a 2-year-old women (patient 29) with a complicated history including embryonic biliary atresia status post
liver transplant, EBV viremia, and upper gastrointestinal Bcell PTLD, polymorphic type. Both had liver biopsies
demonstrating sinusoidal T-cell infiltration mimicking
HSTCL (Fig. 3C), but an immunophenotype of CD3þ/
CD8þ/TIA1þ/Granzyme
Bþ/CD57þ/EBV-/TCRabþ.
Both patients responded to treatment well and continued to
do well on clinical follow-up.
The two patients with T-cell PTLD had very aggressive
clinical course and died of disease within one year of
diagnosis. The first was a 46-year-old women (patient 36)
status after liver transplant for congenital hepatic fibrosis.
Liver biopsy showed portal/sinusoidal infiltrates with an
immunophenotype of CD4þ/TIAþ/Granzyme Bþ/
EBERþ (Fig. 5A). The second was a 9-year-old women
(patient 37) with a history of persistent active hepatitis
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Comparisons between HSTCL and PTCL-NOS.

5–>

HSTCL (n Z 14)

PTCL-NOS (n Z 13)

P value

Age, median, range
Sex
Immunosuppression
due to prior malignancy or IBD

32 (3e71)
2F, 12M
2
2
10
9
2
2
1
0
3
2
9
6
8
0
0
13
0
1
51 (0e619)

57 (26e73)
3F, 10M
0
0
13
6
2
3
2
3
3
1
6
1
5
4
3
8
3
2
76 (14e2600)

0.015
NS
NS

R value

Imaging findings

Histology

Outcomes

Prior malignancy
IBD
None
Cholestatic
Hepatitic
Normal
N/A
Mass
Enlarged
Abnormal
Normal/None
1. Sinusoidal
2. Portal þ sinusoidal
3. Portal þ lobular
4. Massive
DOD
Alive
LTF

Follow-up days

NS

NS

0.008

NS

NS

IBD, inflammatory bowel disease; DOD, died of disease; LTF, lost to follow-up; NS, not significant; HSTCL, hepatosplenic T-cell lymphoma; PTCLNOS, peripheral T-cell lymphoma, not otherwise specified.

(ALT up to 1430 IU/L, R Z 25.3) clinically suspicious for
HLH. Liver biopsy showed portal/lobular small mature
lymphocytic infiltrates, retrospectively stained positive for
EBV (Fig. 5B). She underwent 9 of 10 HLA-matched unrelated donor bone marrow transplant but soon developed
multiple liver mass lesions. The liver biopsy showed a highgrade lymphoma with an immunophenotype of CD4þ/
CD56þ/TIA-1þ/Granzyme Bþ/EBV LMP-1þ (Figs. 4D
and 5C).
The two ALK-negative ALCL cases, one likely being
liver “primary”, occurred in elderly men and presented as
mass lesions on imaging, with mild cholestatic pattern liver
function abnormality. Histology revealed high-grade
cytology with characteristic hallmark cells (Fig. 4A and
B). T-ALL and T-PLL, both secondary liver involvement by
a systemic disease, presented as mass lesions and near
normal liver function tests. Two CTCL (mycosis fungoides), two AITL, and one NK/T had prior diagnosis of
the same lymphoma in skin or lymph node. The one case of
extranodal NK/T-cell lymphoma, nasal type demonstrated
portal and lobular infiltrates (pattern 3), marked hepatotoxicity (R Z 16.7), and strong EBER positivity (Fig. 5D).
With the exception of one AITL, all patients died of disease
upon follow-up.

4. Discussion
In this multi-institutional study, we reviewed a total of
40 cases of T-cell neoplasms diagnosed in the liver to

characterize the clinicopathologic features. The types of
neoplasms in this study covered nearly 70% of the WHO
classification of mature T- and NK-cell neoplasms, the
largest and most comprehensive to date. The majority of
diagnoses were made in liver biopsies with pertinent clinical history and necessary ancillary tests for confirmation.
Our study showed that hepatic T-cell neoplasms occurred in
a wide age range, were male predominant, and had a
generally dismal prognosis. The integrated correlation
analysis on imaging studies, laboratory tests, and histomorphology patterns may serve as a diagnostic guideline
for surgical pathologists who frequently encounter the liver
biopsies before hematopathology consultation and lymphoma work-up.
Hepatic involvement by lymphoma can be difficult to
distinguish from reactive conditions or other malignancies
[12]. Unlike other primary or metastatic neoplasm in the
liver, lymphoma may not form a mass lesion [2]; instead,
the lymphoma cells infiltrate into the hepatic sinusoids or
portal tracts, compressing the hepatic plate and biliary
outflow, causing liver enzyme elevation [13e15]. The
damage to liver is more likely a pushing effect rather than
hepatotoxic, which explains why ALP elevation is more
frequent than transaminitis. The abnormal liver function
tests together with an infiltrative growth pattern without
mass formation frequently mimics drug-induced liver
injury or viral infection. Although radiographic and laboratory tests are not always reliable in detecting lymphoma
[15], correlation with histomorphology increases awareness
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Fig. 5 Epstein-barr virus (EBV) testing in liver biopsies. EBV was detected in a PTLD with portal and sinusoidal infiltrates (A), the 9year-old with chronic EBV infection in pre-transplant liver biopsy (B) and massive high-grade T-cell PTLD after bone marrow transplant
(C), and an extranodal NK/T-cell lymphoma, nasal type (D). Magnification: 200. PTLD, post-transplant lymphoproliferative disorder.

and diagnostic accuracy. On the other hand, a mass-forming
lymphoma may be easier to recognize as a malignancy but
can be difficult to distinguish from other primary or metastatic non-hematopoietic neoplasms [16,17]. Thus, pattern
recognition, morphologic suspicion, and prudent work-up
are key to reaching proper diagnosis.
HSTCL accounted for approximately one-third of all Tcell neoplasms in our cohort. In line with the literature
showing that approximately 20% HSTCL occurred in patients with immunosuppression [18], a similar percentage
of patients with inflammatory bowel disease or prior
diagnosis of other lymphoma/leukemia was found in our
case series. HSTCL is a well-known underlying etiology
for HLH [19], an observation again recapitulated in our
study. The sinusoidal infiltration pattern is characteristic for
HSTCL, but not exclusive, as T-LGL and PTCL-NOS can
have similar histomorphology, therefore relying on IHC or
other ancillary tests for definitive diagnosis. Indeed, a European study published in 2007 showed that HSTCL only
accounted for 1 of 19 T-cell lymphomas involving the liver
[1], strikingly lower than the proportion of HSTCL in our
series. The difference may be partially attributed to
geographic factors but also likely due to more extensive
diagnostic tests to accurately distinguish HSTCL from
other lymphomas.
T-LGL serves as a top differential diagnosis for HSTCL
by histology. Immunophenotypically, T-LGL is typically
CD8þ/TIA1þ/Granzyme Bþ/CD57þ/TCRabþ, despite

some variants and overlaps [20,21]. T-LGL is usually
indolent with lower mortality, in contrast to the rapid progression of HSTCL. A takeaway from the pediatric T-LGL
case in our cohort is to keep in mind that although T-LGL
usually occurs in elderly patients with no associated risk
factors, it happens in all age groups, particularly those with
immunosuppression due to solid organ transplant or treatment for inflammatory bowel disease [22,23].
PTCL-NOS represented the second largest group of Tcell neoplasm in our study. As a diagnosis of exclusion,
PTCL-NOS refers to a heterogeneous group of mature T
cell lymphomas that cannot be classified into a specific
category according to the current WHO classification
[24,25]. Consistent with a general lack of a specific etiology, no prior malignancy diagnosis other than PTCL-NOS
nor history of inflammatory bowel disease were identified
in our case cohort. The majority were that of CD4þ/CD8or CD4-/CD8þ T cells, frequently TCR-abþ, and with loss
of one or more pan-T-cell antigens. While most PTCL-NOS
were diagnosed in lymph nodes, at least two cases showed
initial or predominant liver presentation with mass-forming
lesions, for which we suspected a primary hepatic PTCLNOS. Of note, primary hepatic PTCL-NOS is extremely
rare, some associated with EBV infection [4]. Although we
did not find significant survival differences between “primary” and “secondary” lymphomas in our study, it may
warrant further studies to compare larger cohorts in each
group for potential significant clinical implications.
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EBV is etiologically linked to a wide range of lymphoproliferative disorders and malignant lymphomas
[26,27]. In our study, EBV infection was associated with at
least 3 types of lymphoproliferative disorders: NK/T, AITL,
and PTLD. Interestingly, one PTLD case developed after
bone marrow transplant was retrospectively found to have
chronic active EBV infection in pre-transplant liver biopsy,
stressing the importance of EBV test for some lymphoma
types. EBV þ T-cell PTLD is uncommon, and rare cases of
synchronous EBV þ B- and T-cell PTLD have been reported [28]. Interestingly, the current WHO classification of
T-cell PTLD covers a wide range of T-cell neoplasms
including HSTCL and T-LGL in the clinical setting of solid
organ or bone marrow transplant [8], which makes the two
HSTCL and one T-LGL in our cohort classifiable as EBVnegative T-cell PTLD under that umbrella, revealing the
complexity of lymphoma etiology and overlaps in
classification.
Although only a limited number of cases were tested,
cytogenetics and molecular studies have been playing an
increasingly important role in lymphoma diagnosis and
management [29]. In our cohort, isochromosome 7q was
applied to confirm HSTCL in a very complicated case with
a prior diagnosis of mixed phenotype acute leukemia,
stressing the diagnostic value of cytogenetics in certain
cases. The molecular consequences of isochromosome 7q
in HSTCL is unknown, although many candidate genes
have been proposed [30]. Other genetic or molecular abnormalities are not disease-specific but are helpful in differential diagnosis. For example, activating STAT5
mutations have been reported in multiple PTCL-NOS,
HSTCL, and some aggressive variant of T-LGL [31e33],
suggesting STAT signaling pathway as a common driver
mutation in certain groups of T-cell lymphomas. Overlaps
at the molecular levels and IHC between AITL and PTCLNOS were also reported [34]. One study identified shared
molecular features between NK-cell lymphoma and a group
of non-HSTCL T-cell lymphoma with sensitivity to a novel
aurora kinase A inhibitor [35], suggesting that molecular
tests may not only help understanding lymphomagenesis,
but also revealing therapeutic targets.

5. Conclusion
In summary, we performed the largest comprehensive
study on T-cell neoplasms in the liver to characterize the
clinicopathologic features, covering a wide range of lowgrade vs. high-grade, precursor vs. mature, and primary vs.
secondary T-cell lymphomas/proliferative disorders. An
integrated analysis on imaging, laboratory liver function
tests, histomorphologic features, and immunophenotypes
was performed to provide clues for proper workup and
accurate diagnosis. We focused specifically on common
entities such as HSTCL, PTCL-NOS, T-LGL, and PTLD,
the diagnostic pitfalls, and lessons learned from
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challenging cases. As a heterogeneous group of lymphomas
that is difficult to define and classify, future studies may
focus on large comprehensive testing such as nextgeneration sequencing for more accurate diagnosis, better
classification, and targeted therapy strategies.

Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.humpath.2020.09.007.
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